---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-23-000037"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T14:09:30.228678+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M

## Summary
- Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.
- Nucleic Acid Production revenue $61.5M (-72.5% YoY) includes ~$15.9M COVID-19 CleanCap revenue, $157M less YoY.
- Biologics Safety Testing revenue $17.6M (-14.9% YoY) driven by post-COVID inventory normalization and China slowdown.
- Adjusted EBITDA $23.8M (30.1% margin), down from $187.0M in prior year.

## SEC filing metadata
- accession: 0001823239-23-000037
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/0001823239-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/mrvi-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-23-000037
- JSON: https://secwatch.observer/filing/0001823239-23-000037.json
- Plain text: https://secwatch.observer/filing/0001823239-23-000037.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: revenue $79.0 million, net income $(1.3) million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $79.0 million
  - Net income: $(1.3) million
  - Result: reported results
  source text: Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $79.0 million, Net loss of $(1.3) million, and Adjusted EBITDA margins of 30.1%;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000037/0001823239-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.